CYLD Antibody [FITC]

Product Discontinued

CYLD Antibody [FITC] Summary

• Immunogen: Synthetic peptide made to an internal portion of human CYLD (within residues 500-600). [Swiss-Prot# Q9NQC7]
• Localization: Cytoplasm, perinuclear region.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CYLD
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence
• Application Notes: This CYLD antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot, where a doublet is seen ~120 kDa (Hellerbrand, et al.)
  
  The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Orangutan. Does not react with rat.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Immunogen affinity purified

Notes

This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Alternate Names for CYLD Antibody [FITC]

• BRSS
• CDMT
• CYLD
• CYLD1
• CYLD1MFT
• CYLDI
• cylindromatosis (turban tumor syndrome)
• Deubiquitinating enzyme CYLD
• EAC
• EC 3.1.2.15
• EC 3.4.19.12
• FLJ20180
• FLJ31664
• KIAA0849FLJ78684
• MFT1
• probable ubiquitin carboxyl-terminal hydrolase CYLD
• SBS
• TEM
• ubiquitin carboxyl-terminal hydrolase CYLD
• ubiquitin specific peptidase like 2
• ubiquitin thioesterase CYLD
• Ubiquitin thiolesterase CYLD
• Ubiquitin-specific-processing protease CYLD
• USPL2

Background

CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CYLD